Anlotinib inhibits the proliferation, migration and invasion, and induces apoptosis of breast cancer cells by downregulating TFAP2C

The vascular endothelial growth factor receptor (VEGFR) network contributes to breast cancer pathogenesis and progression. Anlotinib is a highly potent multi-target tyrosine kinase inhibitor that has been previously shown to exert antitumor effects in various types of cancer. The aim of the present...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Fuxiao, Yuan, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674883/
https://www.ncbi.nlm.nih.gov/pubmed/34976158
http://dx.doi.org/10.3892/ol.2021.13164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674883/
https://www.ncbi.nlm.nih.gov/pubmed/34976158
http://dx.doi.org/10.3892/ol.2021.13164

Ejemplares similares